These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 16029069)

  • 1. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
    Kappelhoff BS; Huitema AD; Yalvaç Z; Prins JM; Mulder JW; Meenhorst PL; Beijnen JH
    Clin Pharmacokinet; 2005; 44(8):849-61. PubMed ID: 16029069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
    Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T
    Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
    Kappelhoff BS; van Leth F; MacGregor TR; Lange J; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(1):145-55. PubMed ID: 15751772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
    de Maat MM; Huitema AD; Mulder JW; Meenhorst PL; van Gorp EC; Beijnen JH
    Br J Clin Pharmacol; 2002 Oct; 54(4):378-85. PubMed ID: 12392585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
    Kappelhoff BS; Huitema AD; Crommentuyn KM; Mulder JW; Meenhorst PL; van Gorp EC; Mairuhu AT; Beijnen JH
    Br J Clin Pharmacol; 2005 Feb; 59(2):174-82. PubMed ID: 15676039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic meta-analysis with efavirenz.
    Barrett JS; Joshi AS; Chai M; Ludden TM; Fiske WD; Pieniaszek HJ
    Int J Clin Pharmacol Ther; 2002 Nov; 40(11):507-19. PubMed ID: 12698988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?
    Dahri K; Ensom MH
    Clin Pharmacokinet; 2007; 46(2):109-32. PubMed ID: 17253884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.
    Bednasz CJ; Venuto CS; Ma Q; Daar ES; Sax PE; Fischl MA; Collier AC; Smith KY; Tierney C; Acosta EP; Mager DE; Morse GD;
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30642925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
    Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
    Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.
    DiCenzo R; Forrest A; Squires KE; Hammer SM; Fischl MA; Wu H; Cha R; Morse GD;
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1929-35. PubMed ID: 12760869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.
    Viljoen M; Karlsson MO; Meyers TM; Gous H; Dandara C; Rheeders M
    Eur J Clin Pharmacol; 2012 Apr; 68(4):339-47. PubMed ID: 22057858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.
    Zhao W; Cella M; Della Pasqua O; Burger D; Jacqz-Aigrain E;
    Br J Clin Pharmacol; 2012 Apr; 73(4):641-50. PubMed ID: 21988586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.
    Sam WJ; Tham LS; Holmes MJ; Aw M; Quak SH; Lee KH; Lim SG; Prabhakaran K; Chan SY; Ho PC
    Clin Pharmacokinet; 2006; 45(1):59-75. PubMed ID: 16430311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
    Dumond JB; Nicol MR; Kendrick RN; Garonzik SM; Patterson KB; Cohen MS; Forrest A; Kashuba AD
    Clin Pharmacokinet; 2012 Dec; 51(12):809-22. PubMed ID: 23044523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
    Kappelhoff BS; Huitema AD; Sankatsing SU; Meenhorst PL; Van Gorp EC; Mulder JW; Prins JM; Beijnen JH
    Br J Clin Pharmacol; 2005 Sep; 60(3):276-86. PubMed ID: 16120066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
    Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.
    Regazzi MB; Villani P; Maserati R; Seminari E; Pan A; LoCaputo F; Gambarana E; Fiocchi C
    J Antimicrob Chemother; 2000 Mar; 45(3):343-7. PubMed ID: 10702554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
    López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J
    Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.